A Giant Step Forward — If....

Abstract

The two papers published in this issue of the Journal detailing the excellent preliminary results in the adjuvant therapy of osteogenic sarcoma not only represent a milestone in the treatment of this disease but also hold great promise for the future management of some other more common types of refractory tumors. For many years osteogenic sarcoma has been the "bête noire" of the chemotherapist, in that although the progress of the pulmonary metastases could be carefully followed by chest films, they rarely showed appreciable response to any chemotherapeutic agent. In refractoriness to chemotherapy, osteogenic sarcoma closely approximates the adult tumors . . .